Just prior to the long Memorial Day weekend, the FDA gave the nod to Novartis gene therapy Zolgensma for one of the leading genetic causes of infant death — spinal muscular atrophy (SMA). The approval also grabbed headlines when Novartis announced the price: $2.1 million. Who better to talk about this than Michelle Rivera, an analyst with inThought Research who did her PhD in SMA. Rivera speaks with MM&M’s executive editor Marc Iskowitz about the pathophysiology of the disease, the SMA drug pipeline and how payers may react to what is the most expensive single-dose drug ever.
Please login or register first to view this content.